| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Strategic Planning > Strategic Planning Reinforces Possibility Thinking |
|
Advice You - Strategic Planning Reinforces Possibility Thinking
Strategic planning is all about creating specific strategic (thoughts). The more your people think about the possibilities, According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product the greater likelihood that you will reach farther than you have ever gone before. So what is stopping you? Maybe you alway ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in have had the same people at your strategic planning table. These are good performers who are comfortable with how the compa lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. y is currently performing. Possibly, they have a belief that "If it ain’t broke, why fix it?" The ability to think outside here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe f the box is not their strength. Or you may have different people, but they all reaffirm what you believe, think and do. Th d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro se individuals are the "Yes, boss! You are right boss!" However today, you look out your corner office window or read the ec ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc nomic trends in your daily business journal. Suddenly, you realize that the company is not growing given the DOW is over 13,0 easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi 00 and has reached historical highs in the first six months of 2007. You now know that you are not where you want to be for y nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ur company or even yourself. You sit down and take out your strategic plan that is somewhat dusty. As you read its fresh pag and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s, you see that you have been doing the same things over and over again and getting the same, safe results. However, you hav ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi just finished Blue Ocean Strategy and realize that you are in the red ocean. Now you think: "To go where we have ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a never gone before (the Blue Ocean) and get what we have never got before (incredible results), we must do what we have never dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod one before (take risks, look for possibilities, opportunities)." You recognize that your Strategic Planning process is l cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin cking people who think outside of the box. Who are possibility thinkers. These people think in terms of Yes, it can be d tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen one! and So what if we fail, we just regroup and try another approach. Possibility thinkers are not afraid of tak t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ng risks because they know that success comes from failure. To try is better than to not try at all. Suddenly, you look at ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust our executive team and your employees with a new lens, a new filter. You are now actively seeking individuals who will chall y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products nge the status quo, but who have the leadership skills to wor . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de with your existing executive team. Possibility thinking is the vehicle to drive your strategic plan to that next level of s elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ccess. And you have now learned that possibility thinking begins within the leadership of each individual, starting with you tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Are You Sure It Is A Job You Want? Sales Success Tip-How to Sell to Different Personalities
|